Purpose Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival beneWt for geWtinib (IRESSA) in combination with Wrst-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to geWtinib in combination with chemotherapy. Methods Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay™ (Dako, Denmark). Analyses were stratiWed by trial and performed independently for patients randomized to placebo and geWtinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically signiWcant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors. Results Analyses found two statistically signiWcant EGFRbased prognostic factors representing growth pattern and percent membrane staining in patients treated with geWtinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic eVect was independent of other known prognostic factors. There was no predictive eVect of either the growth pattern or membrane staining variable. Conclusions While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically signiWcant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The eVects of membrane staining and growth pattern are still signiWcant when adjusting for mutation.
Introduction
The identiWcation of factors that may predict survival (i.e., prognostic factors) or response to treatment (i.e., predictive factors) of non-small-cell lung cancer (NSCLC) is an important goal, as it may, in the future, enable identiWcation of patients with better prognosis, or targeting of treatment to those patients most likely to respond. One such factor worthy of consideration is the epidermal growth factor receptor (EGFR), a member of the erbB family of receptors. EGFR, which is expressed or highly expressed in a variety of solid tumors, has been implicated in the pathogenesis of human malignancies and hence is a rational target for anticancer therapies (Salomon et al. 1995; Woodburn 1999) . Expression of EGFR may be demonstrated by means of diVerent techniques; for example, immunoblotting and immunohistochemistry (IHC). Even within one technique, diVerences in primary antibody, epitope retrieval method, visualization system, method of interpretation, and cut-oV level may all aVect the level of EGFR expression recorded. This may partly explain the conXicting results on EGFR as a prognostic indicator (Kallio et al. 2003; Merseburger et al. 2005; Nicholson et al. 2001) .
However, in NSCLC, EGFR expression has a "weak" association with overall survival (OS). Many studies in NSCLC have reported an association of EGFR to poor survival (Ohsaki et al. 2000; Veale et al. 1993; Volm et al. 1998) , while others report a prognostic correlation for EGFR only in combination with other proteins like HER2-neu (Brabender et al. 2001) . However, in a review of the literature, more studies actually failed to show a signiWcant correlation between EGFR expression and OS (Meert et al. 2002) .
In order to determine whether there is any correlation between the level of EGFR expression and OS, exploratory analysis of EGFR expression was performed using diagnostic samples from patients with advanced NSCLC participating in the Phase III INTACT (IRESSA NSCLC Trial Assessing Combination Treatment) trials, which failed to show survival beneWt with geWtinib (IRESSA) Herbst et al. 2004 ). In these studies, no selection based on EGFR expression was performed because this was not correlated with response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in preclinical models (AstraZeneca data on Wle). However, it might be theoretically possible to Wnd a subgroup of patients with a speciWc EGFR pattern, who were predicted to beneWt signiWcantly from treatment. The exploratory objective was to retrospectively identify prognostic indicators for Wrst-line chemotherapy-treated patients. We aimed to determine the prognostic eVect of EGFR in these patients and whether prognostic eVects of EGFR were independent of other known clinical prognostic factors.
Materials and methods

Randomization
All patients were randomized to standard chemotherapy plus one of the following: geWtinib 250 mg/day, geWtinib 500 mg/day, or placebo. Allocation to the three treatment groups was performed by dynamic randomization (Pocock and Simon 1975) to obtain treatment balance for the following stratiWcation factors: weight loss in the previous 6 months ·5% versus >5%; disease stage III versus IV; performance status (PS) of 0 or 1 versus 2; or measurable disease versus non-measurable disease.
Patients
Eligibility criteria have already been reported Herbst et al. 2004 ). The INTACT study was performed in accordance with the Declaration of Helsinki, and patients gave an informed consent prior to inclusion in the study Herbst et al. 2004 ). Donation of tumor samples was not obligatory for participation in the INTACT studies.
Handling and assessment of tissue samples NSCLC tissue samples were obtained prior to start of therapy. The samples were formalin-Wxed and paraYn-embedded according to prespeciWed guidelines. All handling of trial material was performed in compliance with Good Clinical and Good Laboratory Practices' guidelines (International Conference on Harmonisation 2001; Organisation for Economic Co-operation and Development 2007). A medical pathologist, blinded to treatment and outcome, assessed sample evaluability, growth pattern, staining patterns, and staining intensities. Due to the inability to evaluate growth pattern, cytology specimens were excluded from the analysis.
EGFR immunohistochemistry
Tissue specimens were stained by IHC using the validated EGFR pharmDx™ (Dako, Denmark) assay, which utilizes a standard staining protocol (Dako, EGFR pharmDx™ product insert) (Spaulding and Spaulding 2002) . The EGFR pharmDx™ assay detects native EGFR as well as mutant EGFR vIII (Andersen et al. 2004) . Further, the EGFR pharmDx™ assay has been shown not to cross-react with the other three members of the erbB receptor family, erbB2, erbB3, and erbB4 (Andersen et al. 2004; Spaulding and Spaulding 2002) .
Capture of EGFR staining intensities and growth pattern
The pattern of membrane and cytoplasmic staining was assessed in each tumor sample. (Fig. 1a-f ). This was true for both membrane and cytoplasmic staining.
The medical pathologist (MJ) categorized the growth pattern in three categories: (1) solid, (2) glandular, or (3) mixed solid and glandular. (1) For tumors with solid growth pattern, as seen in squamous cell carcinoma, or poorly diVerentiated adenocarcinoma (AC), complete staining of the membrane resulted in a staining pattern, Wguratively described as chicken-wire or Wshnet staining (Fig. 1a-c) . (2) The glandular growth pattern reXects the growth pattern of a well-diVerentiated AC, including, but not restricted to, the growth of bronchioloalveolar carcinoma (BAC). The maximal membrane staining in welldiVerentiated AC is found in the basal and lateral membranes, mirroring the fact that tumor cells of AC with glandular growth are polarized ( Fig. 1d-f) . (3) Tumors with mixed growth pattern (adenosquamous carcinoma) may contain areas with both chicken-wire basolateral-membrane staining. The rationale for capturing complete and basolateral-membrane staining stems from the established scoring system for HercepTest TM (Dako, Denmark), where complete membrane staining in >10% of tumor cells determines eligibility for trastuzumab treatment (Slamon et al. 1989 ).
Statistical analysis
Both the predictive and the prognostic eVects of EGFR were investigated.
An exploratory analysis on OS was performed independently for patients randomized to placebo and to geWtinib (250 or 500 mg/day), as well as for combined treatment groups. Analyses were stratiWed by trial. A restricted Fig. 1 Photomicrographs of squamous cell carcinoma (SC) (a-c) and well diVerentiated adenocarcinoma (AC) (d-f) immunostained with the Dako (EGFR) pharmDx™ assay. In SC the growth pattern is solid. When the entire circumference of the cell membrane is stained positive, the impression of the tumor is that of chicken-wire or Wshnet. In AC the growth pattern is glandular, allowing for a basolateral staining when the entirety of the membrane is stained. The cell membrane may have diVerent staining intensities: a and d weak 1+ staining; b and e moderate 2+ staining; c and f strong 3+ staining backwards elimination Cox proportional hazard regression analysis, by which only biologically relevant eliminations took place in each step, was conducted. In each step, the statistical model contains a term for up to three variables (intensity level 1+, 2+, and 3+) within each of three categories: (a) membrane, (b) complete or basolateral, and (c) cytoplasmic staining. Tests are restricted to coeYcients of all pairs of adjacent variables within the same category being equal. For example, the test of the coeYcient to the variable at the lowest level (1+) being equal to zero is considered as a test for collapsing this level with the no staining level. Additionally, let us assume that in a previous step the hypothesis that the eVect of staining being at level +1 and +2 is accepted as being equal, leading to the adjoining of these two levels, then testing that the coeYcient to the adjoined level is equal to zero is identical to testing whether the adjoined level (1+ and 2+) could be further combined with the no staining level, and thereby removed from the model. In each step the test producing the largest P value determines the candidate to be adjoined next.
The analyses were conducted to identify categorical and continuous EGFR factors (growth pattern, membrane, and cytoplasmic staining intensity and completeness of membrane staining) prognostic for survival within the group of placebo and geWtinib-treated patients, separately as well as combined. Variables found to have a statistically signiWcant prognostic eVect within at least one of the two treatment groups were also tested for treatment interaction, to determine if they served as predictive factors.
It was further analyzed whether EGFR-related variables, found to be statistically signiWcant prognostic factors, had an eVect of their own, independent of other potential prognostic factors such as gender, PS, stage, histology, and site of metastasis. This was done by repeating the above-mentioned procedure based on the EGFR-related variables in combination with the potential clinical prognostic factors.
Tests were performed at the 10% two-sided signiWcance level (i.e., P < 0.10 was considered statistically signiWcant).
Results
Demographics
A total of 631 patients had tumor samples available and provided consent to this exploratory part of the INTACT studies. Tissue samples that were fully evaluable for EGFR were available for 516 patients (219 and 297 from INTACT 1 and 2, respectively).
Comparison of the demographic factors and patient disease characteristics such as histology, PS, stage, and site of metastasis revealed that this patient population, with a tumor sample fully evaluable for EGFR, was similar to that of both INTACT trials from whom tumor samples were less than fully evaluable for EGFR or not evaluable, and representative of the full INTACT population (data on Wle).
Prognostic and predictive eVect
Prognostic eVect
The two EGFR-related variables of growth pattern and membrane staining were found to have statistically signiWcant prognostic eVects, both in patients treated with geWtinib (P = 0.0023) and placebo (P = 0.0128), as well as in the two groups combined (P < 0.0001) ( Table 1) .
There was no statistically signiWcant diVerence in OS between patients having tumors with a glandular growth pattern and those having tumors with a mixed growth pattern in either of the treatment groups (data not shown). Therefore, these patients (glandular/mixed) were combined and will subsequently be referred to as "glandular patients". The others will be referred to as "solid patients". Glandular patients had statistically signiWcantly better survival than solid patients when the two treatment groups were combined (P = 0.0001) or considered separately (placebo, P = 0.0220; geWtinib, P = 0.0014) ( Table 1 ). This prognostic eVect was of the same magnitude in both treatment groups.
The total percentage of cytoplasmic staining and the total percentage of membrane staining were highly correlated (r = 0.92). EGFR expression, as measured by membrane staining, had the strongest prognostic eVect of the two, and conditioned on this eVect, cytoplasmic staining had no prognostic eVect of its own. All further analyses were consequently focused on membrane staining. The percentage of membrane staining had a statistically signiWcant prognostic eVect as a continuous covariate in both treatment groups (placebo, P = 0.0147; geWtinib, P = 0.0463) and in both groups combined (P = 0.0025) ( Table 1 ). In the placebo group, the most statistically signiWcant variable was membrane staining of weak (1+), moderate (2+) or strong (3+) intensity, whereas in the geWtinib group it was the variable "membrane staining of moderate (2+) or strong (3+) intensity". According to the prespeciWed procedure, two variables, "membrane staining of weak (1+)" and "moderate (2+) or strong (3+)", were analyzed based on both treatment groups combined, resulting in identifying membrane staining of weak (1+), moderate (2+), or strong (3+) intensity as the most statistically signiWcant variable. As membrane staining is a continuous covariate, the eVect of membrane staining is a trend eVect. The hazard ratio (HR) is calculated based on membrane staining of 0 or 100%, only.
The prognostic eVect of both EGFR-related variables (growth pattern and membrane staining) is of the same size in terms of HR, consistent over treatment groups and independent of other prognostic factors (Table 1) . A further exploration of the trend eVect is shown in Fig. 2a (solid growth pattern) and b (glandular growth pattern), which show the median survival times predicted by the Cox proportional hazard model, incorporating membrane staining as a continuous covariate, i.e., a trend eVect of membrane staining. As shown in Fig. 2a and b, with many groups containing small numbers of patients, it was expected that the variability of the estimated medians around the predicted trend was large, indicated by the wide conWdence intervals (CIs). In all cases, where both upper and lower 99% conWdence limits could be estimated, the interval included the median time predicted by the Cox proportional hazard trend model, suggesting a reasonable model Wt. However, a lack of Wt test rejected the null hypothesis that the data Wtted the Cox proportional hazard trend model (P = 0.0240). The lack of Wt may be caused by deviation from the trend model, or because of a lack of proportional hazard.
The prognostic trend eVect appears to be more pronounced in patients having a glandular growth pattern (Fig. 2b) than in those having a solid growth pattern (Fig. 2a) . Since the interaction eVect between growth pattern and percentage membrane staining was not statistically signiWcant (P = 0.1474), the prognostic trend eVect may be the same for all patients. In spite of this, the prognostic trend eVect in the glandular growth pattern group was highly statistically signiWcant (P = 0.0035), whereas the trend eVect in the solid growth pattern group was not statistically signiWcant (P = 0.1094), yet another possibility is that percentage membrane staining only has a prognostic trend eVect in the group of patients not having a solid growth pattern.
Prognostic eVect using alternative scoring method
An additional post-hoc analysis of the EGFR expression data from the INTACT trials was conducted, to facilitate a comparison between the data presented here, and the results of the erlotinib BR21 trial . In this analysis, EGFR-positive was deWned as ¸10% of cells staining positive for EGFR. Using this scoring system, 459 (89%) and 57 (11%) patients were found to be EGFR-positive and EGFR-negative, respectively. When both treatments groups were combined, the median survival for the EGFR-positive group was 307 days with 261 days for the EGFR-negative group; the HR comparing the positive to negative groups was 0.812 (95% CI = 0.588-1.123), suggesting similar results to the original analysis that patients with EGFR expression have a better prognosis in this study.
To look for a predictive eVect, the geWtinib treatment group contained 312 EGFR-positive and 40 EGFR-negative classed patients with a median survival 296 and 218 days, respectively. An HR of 0.959 (95% CI = 0.635-1.449) was estimated in Cox regression analysis with a P value of 0.84.
Comparison with other clinical prognostic factors
To illustrate how strong the prognostic eVect of the two EGFR-related variables is (growth pattern and staining intensity), the eVect of these variables was compared with other well-known clinical prognostic factors. The strength of the eVect of the EGFR prognostic factor related to growth pattern expressed as an HR (solid vs. glandular) was 0.668 (95% CI = 0.525-0.850) ( Table 1) . The strength of the prognostic eVect of membrane staining at weak (1+), moderate (2+), or strong (3+) intensity, when shifting from 0 to 100%, was similar. This maximum shift from 0 to 100% membrane staining gave a 30% improvement in survival (HR 0.694; 95% CI = 0.516-0.934) ( Table 1) .
To further illustrate the strength of the prognostic eVect of the two EGFR-related variables, the Kaplan-Meier plots for growth pattern (Fig. 3a) and membrane staining (Fig. 3b) were compared with those for disease stage III versus IV (Fig. 3c) , as stage of disease showed the strongest prognostic eVect in the original INTACT eYcacy analysis.
Relationship between growth pattern and histology
Because it was expected that histology and growth pattern were at least partially confounded, it was further investigated whether growth pattern had an independent eVect which could not be explained by the recorded histology on the original six-category scale. This was done in spite of the fact that the dichotomized histology variable (AC [including BAC] vs. other histologies) did not have a statistically signiWcant prognostic eVect on survival.
Since all BACs had a glandular growth pattern, it was not possible to distinguish an eVect of histology and growth pattern. BAC, which is a subgroup of AC, was therefore excluded when investigating dependence between histology and growth pattern (14 patients with eight deaths).
The analysis showed that the eVect of the two EGFR prognostic factors (growth pattern and membrane staining) was statistically signiWcant in the group of patients with AC excluding BAC (P = 0.0019 and P = 0.0137, respectively). The strength of the eVect of the two EGFR prognostic factors was similar to that observed when all (516) specimens were analyzed (data not shown). It is not relevant to test the eVect of growth pattern in the group of non ACs. The eVect of membrane staining was more pronounced in the AC group than in the heterogeneous group of patients with other histologies (excluding BAC), HRs being 0.60 (95% CI = 0.40-0.90) and 0.75 (95% CI = 0.47-1.17), respectively.
Relationship between growth pattern and histology to mutation and ampliWcation of EGFR
A post-hoc analysis was conducted to look at the eVect of EGFR mutation and ampliWcation status on the results seen for staining intensity and growth pattern in a subset of patients also looked at in the recent report by Bell et al. (2005) (Bell et al. 2005) . Of the 516 patients in the analysis of staining intensity and growth pattern, 246 (47.7%) had suYcient DNA for EGFR mutation testing and 387 (75%) had suYcient DNA for measurement of gene ampliWcation by DNA sequencing. For EGFR mutation, 25 (20.2%) patients were found to contain an EGFR mutation while 225 were classiWed as mutation-negative, leaving 270 with missing EGFR-mutation status. For EGFR ampliWcation, 25 (6.4%) patients had EGFR gene ampliWcation, 362 (93.6%) were EGFR ampliWcation-negative, with 129 classiWed as "missing".
For the statistical analysis, three groups were considered, "positive" (either deWned as containing mutation or ampliWcation in the respective analysis), "negative" or "missing". AmpliWcation was found to have no eVect or correlation with either staining intensity or growth pattern, and also had no prognostic eVect alone in a model with both treatments combined. For the analysis of EGFR mutation in the model with staining intensity and growth pattern, EGFR mutation was found to be prognostic (P = 0.03), and both staining intensity (P = 0.007) and growth pattern (P = 0.0005) maintained signiWcant prognostic eVects as well.
Predictive eVect
Neither the growth pattern nor the EGFR membrane staining variable had a statistically signiWcant predictive eVect. This was illustrated in an analysis of a model including treatment, growth pattern (solid vs. glandular group) and membrane staining, together with the interactions between treatment and growth pattern, and treatment and membrane staining. The P values for the test of interactions in this model were P = 0.8688 for treatment and growth pattern, and P = 0.4967 for treatment and membrane staining. Based on this model, including the eVects of the two interactions, the HR and corresponding 95% CI between geWtinib and placebo were estimated for four populations: each of the growth patterns, solid and glandular, with either 0 or 100% membrane staining ( Table 2 ). The wide CIs within each of the four populations indicate that even though no statistically signiWcant predictive eVect was found, the sample sizes were not large enough to exclude the existence of a clinically signiWcant predictive eVect.
Discussion
The results from the current analysis of the two large, Phase III INTACT 1 and 2 studies represent the largest analysis of EGFR expression and OS in patients with NSCLC to date. The INTACT results provide highly statistically signiWcant evidence that EGFR expression, as measured by percentage-membrane staining using the EGFR pharmDx™ assay, is a strong independent prognostic indicator for improved survival in patients treated with platinum-based chemotherapy with tumors that exhibit glandular growth pattern. It may be speculated whether the prognostic trend eVect found in the present studies reXects a true prognostic eVect of EGFR staining in tumors with glandular growth pattern, or whether these tumors respond better to Wrst-line platinum-based chemotherapy.
The prognostic trend eVect of percentage-membrane staining in patients with a solid growth pattern is more uncertain, ranging from no eVect to the same eVect as for patients with a glandular growth pattern (Bingle et al. 2005) . In this analysis, patients with tumors exhibiting areas of well-diVerentiated AC (i.e., glandular growth pattern comprised of AC, BAC, and adenosquamous carcinomas) had better survival than those with tumors that had a solid growth pattern. In addition to prognostic factors, which have eVects on survival irrespective of treatment, much research is being undertaken in an attempt to identify factors that may predict response to treatment. The results from the present analysis showed that neither growth pattern nor EGFR-membrane staining had a statistically signiWcant predictive eVect. However, the study may have been limited by power, given that tumor samples were not mandatory and were only obtained from less than one-third of patients. Furthermore, in these INTACT studies, geWtinib was in combination with chemotherapy and any geWtinib-treatment eVect may have been masked by the combination. Additionally, given the overall result of both trials, in which addition of geWtinib to chemotherapy did not result in superior eYcacy, a predictive eVect is less likely to be seen.
Results from the TALENT (Tarceva Responses in Conjunction with Cisplatin and Gemcitabine) and TRIBUTE (Tarceva Responses in Conjunction with Paclitaxel and Carboplatin) studies demonstrated that the addition of another EGFR-TKI, in this case erlotinib, to standard chemotherapy regimens also did not improve outcome for chemotherapy-naive patients with advanced NSCLC . As with INTACT 1 and 2, and geWtinib, the level of EGFR expression in both TALENT and TRIBUTE were not predictive of responses to erlotinib (Gatzemeier et al. 2007; Herbst et al. 2004 Herbst et al. , 2005 .
Exploratory analysis of 157 tumor biopsies from patients participating in the Phase II IDEAL (IRESSA Dose Evaluation in Advanced Lung cancer) trials revealed that tumor EGFR-membrane staining is not clinically relevant for predicting response in patients receiving geWtinib monotherapy for pretreated advanced NSCLC (Bailey et al. 2003) .
In the Phase III ISEL (IRESSA Survival Evaluation in Lung cancer) trial that failed to demonstrate an overall survival of geWtinib as compared to placebo in patients who had failed chemotherapy (Thatcher et al. 2005) , analysis of tumor biopsy samples demonstrated that EGFR protein expression-positive patients achieved signiWcantly better survival with geWtinib versus placebo than patients with EGFR protein expression-negative tumors (interaction test for EGFR protein expression-positive vs. EGFR protein expression-negative patients, P = 0.049). Better response rates were also reported for EGFR protein expression-positive patients than EGFR protein expression-negative patients (8.2 vs. 1.5%) (Hirsch et al. 2006) . Furthermore, results from the randomized, placebo-controlled trial of erlotinib in patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen (BR21), suggest a correlation between EGFR expression and survival Tsao et al. 2005) . Erlotinib prolonged survival in the EGFR-positive subgroup (n = 184; HR 0.68; 95% CI = 0.49-0.95; P = 0.02), but did not appear to have an eVect on survival in the EGFR-negative subgroup (n = 141; HR 0.93; 95% CI = 0.63-1.36; P = 0.70).
As EGFR expression was measured using a diVerent scoring method in the erlotinib BR21 trial from that used in this analysis of EGFR in the INTACT trials, an additional post-hoc analysis (data not shown) was conducted looking at the eVect of EGFR expression with the same deWnition, from BR21 (¸10% of cells staining positive equals EGFRpositive). This analysis suggested no statistically signiWcant diVerences between EGFR-positive and -negative patients, when treated with geWtinib in combination with chemotherapy.
Emerging data indicate that mutations in the EGFR gene are associated with dramatic responses to geWtinib (Lynch et al. 2004; Paez et al. 2004; Sordella et al. 2004 ). Mutation analysis of samples from INTACT 1 and 2 did not show a statistically signiWcant diVerence in response to geWtinib plus chemotherapy according to EGFR genotype (Bell et al. 2005) . OS was not aVected by the addition of geWtinib to chemotherapy in patients with EGFR mutations (HR = 1.77; 95% = CI 0.50-6.23). However, patients with EGFR-mutation-positive tumors treated with chemotherapy alone had a better OS compared to patients with mutationnegative tumors (median OS, 19.4 vs. 9.2 months; HR = 0.48; 95% CI = 0.29-0.82), raising the possibility that this genetically deWned subset of NSCLC may have a more favorable natural history, and that EGFR mutations may also serve as a prognostic factor. Our analysis of a subset of these same patients included in the current analysis Wnds similar results for the prognostic eVect.
As in other reports, mutational status of tumors from BR21 was shown to possibly increase responsiveness to erlotinib. The response rate among patients with mutations was twice that among patients with wild-type EGFR, although the diVerence was not signiWcant, perhaps because the number of responses was small: 7% of those with wildtype EGFR had a response compared with 16% of those with an EGFR mutation (P = 0.37) (Tsao et al. 2005) . Importantly however, the risk of death did not diVer signiWcantly among patients with EGFR mutations who received erlotinib compared with patients who received placebo (HR = 0.77; 95% CI = 0.40-1.50; P = 0.54), or among patients with wild-type EGFR who received erlotinib compared with such patients who received placebo (HR = 0.73; 95% CI = 0.49-1.10; P = 0.13).
In a recent report from Eberhard et al. (Eberhard et al. 2005; Kishi et al. 2005) , EGFR mutations were found in 13% of tumor samples from patients treated in the TRIB-UTE study ) and was associated with longer survival irrespective of treatment (P < 0.001). This data suggests that EGFR mutation is prognostic of longer survival rather than predictive. However, among patients treated with erlotinib, EGFR mutations were associated with a better response rate and trend towards better time to progression but no survival increase (P < 0.05, 0.092 and 0.96, respectively). On the other hand, K-ras mutations were associated with a signiWcant decrease in time to progression and survival in patients treated with erlotinib.
Many other biomarkers are under investigation as predictive factors, for example, the components of the Akt and MAPK signaling pathways. Indeed, patients with tumors that were positive for phosphorylated Akt (pAkt) have been shown to have a better response rate, disease control rate, and time to progression with geWtinib than those that were negative (Cappuzzo et al. 2004 ). The data from 78 patients treated in Japan with geWtinib showed that pAkt was not predictive of response (Kishi et al. 2005) .
Further work has investigated the relationship between EGFR gene copy number (assessed by Xuorescence in situ hybridization [FISH] ), EGFR mutations, EGFR protein expression and Akt activation status as predictive markers for geWtinib therapy in advanced NSCLC (Cappuzzo et al. 2005) . In a multivariable analysis, high EGFR gene copy number was signiWcantly associated with better survival (HR = 0.44; 95% CI = 0.23-0.82), indicating that this may be a molecular predictor for geWtinib eYcacy in advanced NSCLC. The analysis of tumor biopsy samples from patients participating in the ISEL trial has also demonstrated that high EGFR gene copy number was a predictor of increased survival with geWtinib (comparison of HRs high vs. low copy number, P = 0.045) (Hirsch et al. 2006 ). AmpliWcation of EGFR was associated with responsiveness to erlotinib (P = 0.03) in tumor samples from BR21 subjected to FISH (Tsao et al. 2005) .
The current analysis in Wrst-line, platinum-based, chemotherapy-treated patients with NSCLC provides statistically signiWcant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting.
The prognostic trend eVect of percentage membrane staining in patients with a solid growth pattern is more uncertain, ranging from no eVect to the same eVect as for patients with a glandular growth pattern. In this analysis, patients with tumors exhibiting areas with well-diVerentiated AC (i.e., glandular growth pattern) had better survival than those with tumors that had a solid growth pattern. This is in agreement with earlier studies, which have shown that NSCLC patients with well-diVerentiated tumors survive longer than patients with poorly diVerentiated tumors (Gawrychowski et al. 2003; Nakayama et al. 1997 ).
In summary, many factors may have contributed to the lack of a survival beneWt for geWtinib in combination with Wrst-line platinum-based chemotherapy. The debate continues on the usefulness of EGFR expression to help select patients for treatment. The combination of EGFR expression and growth pattern may be a strong prognostic indicator for improved survival, while high EGFR gene copy number and EGFR mutations could be associated with better response to EGFR-TKIs.
